Oramed Pharmaceuticals Inc.
(ORMP) – NasdaqCM

6.07
-0.47 (-7.19%)
Refresh Quote
Exchange :NASDAQ (US Dollar)
Ric Code :ORMP
Volume :309,672
Date :10-07-2022

* Minimum 20 minute delay See terms

Oramed Pharmaceuticals (NASDAQ: ORMP) has developed innovative technology to transform injectable treatments into oral therapies.

Oramed’s flagship product, an oral insulin capsule, can better the lives of millions of diabetics around the world – allowing, amongst other things, type 2 patients to begin insulin therapy earlier without fear of needles… [READ MORE >]

Oramed Subsidiary Oravax Reports Positive Preliminary Phase 1 Data for its Oral Covid-19 Vaccine

10月 7th, 2022|Oramed Subsidiary Oravax Reports Positive Preliminary Phase 1 Data for its Oral Covid-19 Vaccine已关闭评论

Primary and secondary endpoints of safety and immunogenicity met Oral vaccine elicited a potentially protective IgG response with significant seroconversion from baseline Trial shows proof of concept for oral delivery of vaccines using Oravax technology [...]

Oramed Reports Positive Top-Line Results from Phase 2 NASH Trial with its ORMD-0801, Oral Insulin Candidate

9月 13th, 2022|Oramed Reports Positive Top-Line Results from Phase 2 NASH Trial with its ORMD-0801, Oral Insulin Candidate已关闭评论

Primary endpoint met: ORMD-0801 was safe and well tolerated Secondary endpoint met: ORMD-0801 showed clinically meaningful reduction of liver fat from baseline at 12 weeks Strong evidence for treatment of NASH using Oramed's oral insulin [...]

Oramed to Present at H.C. Wainwright 24th Annual Global Investment Conference

9月 6th, 2022|Oramed to Present at H.C. Wainwright 24th Annual Global Investment Conference已关闭评论

NEW YORK, Sept. 6, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Chief Executive Officer Nadav [...]

Oramed Reaches 50% Enrollment in its Second Phase 3 Oral Insulin Trial

7月 26th, 2022|Oramed Reaches 50% Enrollment in its Second Phase 3 Oral Insulin Trial已关闭评论

-  ORA-D-013-2 is the second of two Phase 3 trials under FDA protocol -  ORA-D-013-1, the larger of the two trials, completed enrollment with top line data expected January 2023 NEW YORK, July 26, 2022 [...]